A comprehensive genetic screen reveals new cellular trafficking factors and linker-dependent requirements for antibody–drug conjugate (ADC) cytotoxicity. These new insights may guide the design of optimized ADCs.
References
Mukherjee, A. et al. Hum. Antibodies 27, 53–62 (2019).
Coats, S.et al. Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-0272 (2019).
Abdollahpour-Alitappeh, M. et al. J. Cell. Physiol. 234, 5628–5642 (2019).
Tsui, C. K.et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-019-0342-2 (2019).
Hamblett, K. J. et al. Cancer Res. 75, 5329–5340 (2015).
Vaites, L. P., Paulo, J. A., Huttlin, E. L. & Harper, J. W. Mol. Cell. Biol. 38, e00392–17 (2017).
Gébleux, R., Stringhini, M., Casanova, R., Soltermann, A. & Neri, D. Int. J. Cancer 140, 1670–1679 (2017).
Kang, J. C. et al. Nat. Biotechnol. 37, 523–526 (2019).
Chalouni, C. & Doll, S. J. Exp. Clin. Cancer Res. 37, 20 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors are employees of Seattle Genetics, a company engaged in the field of antibody–drug conjugates.
Rights and permissions
About this article
Cite this article
Van Epps, H.A., Senter, P.D. Breaking up is hard to do. Nat Chem Biol 15, 934–935 (2019). https://doi.org/10.1038/s41589-019-0351-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-019-0351-1
- Springer Nature America, Inc.